



TAKEDA ONCOLOGY IS PLEASED TO PRESENT:

THE EVOLVING ONCOLOGY PRACTICE MODEL

Navigating a Dynamic Landscape

An Overview of Value, Quality, and Trends Affecting Patient Care

The ongoing shift to value-based care is having a profound impact on the practice of oncology. In recent years, this shift has been marked by the growing adoption of clinical pathways, the emergence of advanced alternative payment models, and innovative payer-provider collaborations. In addition, the healthcare landscape is being transformed as health plans, physician organizations, and pharmacy benefit managers (PBMs) merge and grow.

Takeda Oncology has developed the Evolving Oncology Practice Model informational series to provide the oncology provider community with an overview of the latest trends affecting oncologists and their patients.

This series of presentations will explore the following important areas:

MEDICARE PAYMENT REFORM

- Implementation of new Medicare payment models, which include the Merit-based Incentive Payment System (MIPS) and the Oncology Care Model (OCM), with key outcomes for each track

STANDARDIZING CARE DELIVERY AND IMPROVED OUTCOMES

- The design, intent, and the most common components of clinical pathways in oncology
- Outcomes-based contracts and the challenges to implementation in oncology
- Best practices for supporting patients taking oral oncolytic therapies

TRENDS IN HEALTH PLAN COVERAGE THAT CAN AFFECT PATIENTS WITH CANCER

- The effects of High-Deductible Health Plans (HDHPs) and out-of-pocket costs on patient care
- The growth of Medicare Advantage plans and step therapy as a utilization management tool in Medicare Part B

THE CHANGING PRACTICE OF ONCOLOGY

- Vertical integration of hospitals and providers, as well as Payers and PBMs, and the impact on provider and patient access
- The use of telemedicine and the effect of reimbursement on its clinical implementation

Takeda provides this presentation for informational purposes only. It is the responsibility of providers, physicians and suppliers to determine and submit appropriate codes, charges and modifiers for products, services, supplies, procedures, or treatment furnished or rendered. The information provided herein is without any other warranty or guarantee of any kind, expressed or implied, as to completeness, accuracy, or otherwise.

All trademarks are property of their respective owners. ©2021 Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. All rights reserved.
2/21 MAT-USO-NON-19-00101



ONCOLOGY